[go: up one dir, main page]

EP3289094B1 - Compositions et méthodes d'évaluation de toxicité au moyen d'un profilage bh3 dynamique - Google Patents

Compositions et méthodes d'évaluation de toxicité au moyen d'un profilage bh3 dynamique Download PDF

Info

Publication number
EP3289094B1
EP3289094B1 EP16787045.0A EP16787045A EP3289094B1 EP 3289094 B1 EP3289094 B1 EP 3289094B1 EP 16787045 A EP16787045 A EP 16787045A EP 3289094 B1 EP3289094 B1 EP 3289094B1
Authority
EP
European Patent Office
Prior art keywords
percent
agent
cells
less
aliquot
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16787045.0A
Other languages
German (de)
English (en)
Other versions
EP3289094A4 (fr
EP3289094A1 (fr
Inventor
Anthony Letai
Patrick BHOLA
Jeremy RYAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of EP3289094A1 publication Critical patent/EP3289094A1/fr
Publication of EP3289094A4 publication Critical patent/EP3289094A4/fr
Application granted granted Critical
Publication of EP3289094B1 publication Critical patent/EP3289094B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • Dynamic BH3 Profiling is a technique used to measure the sensitivity of cells to a test compound or therapeutic. Dynamic BH3 profiling is applied to a cancer cell sample, and drugs that move the cancer cells in that sample closer to the threshold of programmed cell death can be readily identified. The drugs so identified are those likely to provide clinical anticancer benefit to the subject from which the cancer cell sample was derived, thereby providing personalized therapy for individual cancer patients.
  • the present disclosure relates to the discovery that the principles of dynamic BH3 profiling can be utilized to assess the toxicity of an agent in non-cancerous cells.
  • the disclosure provides methods for determining how an agent alters the apoptotic sensitivity of non-cancerous cells.
  • the disclosure provides a method of screening a plurality of agents for determining toxicity, said method comprising: a) providing a plurality of agents; b) providing a test aliquot of a sample of cells for each of the plurality of agents, wherein the sample of cells are non-cancerous cells obtained from a subject; c) separately contacting each test aliquot with its respective agent; d) providing a control aliquot of the sample of cells, wherein the control aliquot is not contacted with any of the plurality of agents; e) permeabilizing the cells in each aliquot; f) contacting the permeabilized cells with a pro-apoptotic BH3 domain peptide; g) determining a value for percent BH3 domain peptide-induced mitochondrial outer membrane permeabilization (MOMP) in the cells in each of the test aliquots; h) determining a value for percent BH3 domain peptide-induced MOMP in the cells in the control aliquot; and
  • MOMP mitochondrial
  • the method further comprises conducting in vivo toxicity testing with the agent in a non-human animal or in vitro toxicity testing with the agent if the delta percent priming is 20 percent or less, 18 percent or less, 16 percent or less, 14 percent or less, 12 percent or less, 10 percent or less, 8 percent or less, 6 percent or less, 4 percent or less, 2 percent or less, or 1 percent or less.
  • the non-cancerous cells are healthy cells.
  • the method further comprises j) providing a test aliquot of a sample of cancerous cells obtained from a subject for each of the plurality of agents; k) separately contacting each test aliquot with its respective agent; 1) providing a control aliquot of the sample of cancerous cells, wherein the control aliquot is not contacted with any of the plurality of agents; m) permeabilizing the cancerous cells in each aliquot; n) contacting the permeabilized cancerous cells with a pro-apoptotic BH3 domain peptide; o) determining a value for percent BH3 domain peptide-induced MOMP in the cancerous cells in each of the test aliquots; p) determining a value for percent BH3 domain peptide-induced MOMP in the cancerous cells in the control aliquot; and q) determining a value for delta percent priming for each of the test aliquots, wherein delta percent priming is the difference between the value for percent MOMP determined in (o) and the value
  • the method further comprises conducting in vivo or in vitro toxicity testing with the agent in a non-human animal if the delta percent priming in the cancerous cells is greater than 20 percent, greater than 30 percent, greater than 40 percent, greater than 50 percent, greater than 60 percent, greater than 70 percent, greater than 80 percent, greater than 90 percent, greater than 95 percent, or 100 percent.
  • the method further comprises conducting in vivo toxicity testing with the agent in a non-human animal or in vitro toxicity testing with the agent if the delta percent priming in the cancerous cells is greater than the delta percent priming in the non-cancerous cells.
  • the method further comprises conducting in vivo toxicity testing with the agent in a non-human animal or in vitro toxicity testing with the agent if the delta percent priming in the cancerous cells is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, or at least 200%, greater than the delta percent priming in the non-cancerous cells.
  • the method further comprises conducting in vivo toxicity testing with the agent in a non-human animal or in vitro toxicity testing with the agent if the delta percent priming in the cancerous cells is at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold greater than the delta percent priming in the non-cancerous cells.
  • the cancerous cells are primary human tumor cells. In some embodiments, the cancerous cells are obtained from a patient derived xenograft (PDX).
  • PDX patient derived xenograft
  • the plurality of agents includes 20 or more agents. In some embodiments, the plurality of agents includes 100 or more agents.
  • each test aliquot is contacted with its respective agent for 24 hours or less.
  • the permeabilized cells are contacted with the pro-apoptotic BH3 domain peptide for 3 hours or less.
  • the cells in each of the test aliquots are permeabilized with digitonin or saponin.
  • the percent BH3 domain peptide-induced MOMP is determined by one or more of: i) contacting the cells with a potentiometric dye and measuring the emission of said potentiometric dye; ii) measuring the release of a molecule from the mitochondrial intermembrane space; and iii) measuring the retention of a molecule from the mitochondrial intermembrane space.
  • the potentiometric dye is 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1), dihydrorhodamine 123, tetramethylrhodamine methyl ester (TMRM), or tetramethylrhodamine ethyl ester (TMRE).
  • the molecule from the mitochondrial intermembrane space is cytochrome c, SMAC/Diablo, Omi, adenylate kinase-2, or apoptosis-inducing factor.
  • the BH3 domain peptide is derived from the BH3 domain of a BID, a BIM, a BAD, a NOXA, a PUMA, a BMF, or an HRK polypeptide. In some embodiments, the BH3 domain peptide is selected from the group consisting of SEQ ID NO: 1-16.
  • an agent from the plurality of agents comprises one or more compounds.
  • an agent from the plurality of agents is an anticancer agent.
  • an agent from the plurality of agents is a chemotherapeutic agent.
  • one or more of the plurality of agents are selected from small organic molecules, small inorganic molecules, peptides, proteins, protein analogs, enzymes, nucleic acids, nucleic acid analogs, antibodies, antigens, hormones, lipids, polysaccharides, growth factors, viruses, cells, bioactive agents, pharmaceutical agents, and combinations and prodrugs thereof.
  • one or more of the plurality of agents are selected from gases, fine particles, radiation, electromagnetic radiation, and aerosols.
  • the disclosure provides a method of predicting toxicity of an agent to a tissue, said method comprising: a) providing an agent; b) providing a test aliquot of each of a plurality of cell samples, wherein each cell sample comprises non-cancerous cells obtained from a tissue of a subject; c) separately contacting each test aliquot with the agent; d) providing a control aliquot of each of the plurality of cell samples, wherein the control aliquot is not contacted with the agent; e) permeabilizing the cells in each test aliquot and control aliquot; f) contacting the permeabilized cells with a pro-apoptotic BH3 domain peptide; g) determining a value for percent BH3 domain peptide-induced MOMP in the cells in each test aliquot; h) determining a value for percent BH3 domain peptide-induced MOMP in the cells in each control aliquot; and i) determining a value for delta percent priming for each test
  • the method further comprises conducting in vivo toxicity testing with the agent in a non-human animal or in vitro toxicity testing with the agent if the delta percent priming is 20 percent or less, 18 percent or less, 16 percent or less, 14 percent or less, 12 percent or less, 10 percent or less, 8 percent or less, 6 percent or less, 4 percent or less, 2 percent or less, or 1 percent or less.
  • the non-cancerous cells are healthy cells.
  • the cells are mammalian cells.
  • the cells are derived from samples obtained by biopsy or autopsy of an animal.
  • the cells in each test aliquot are contacted with the agent for 24 hours or less.
  • the permeabilized cells are contacted with the pro-apoptotic BH3 domain peptide for 3 hours or less.
  • the cells are permeabilized with digitonin or saponin.
  • the percent BH3 domain peptide-induced MOMP is determined by one or more of: i) contacting the cells with a potentiometric dye and measuring the emission of said potentiometric dye; ii) measuring the release of a molecule from the mitochondrial intermembrane space; and iii) measuring the retention of a molecule from the mitochondrial intermembrane space.
  • the potentiometric dye is 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1), dihydrorhodamine 123, tetramethylrhodamine methyl ester (TMRM), or tetramethylrhodamine ethyl ester (TMRE).
  • the molecule from the mitochondrial intermembrane space is cytochrome c, SMAC/Diablo, Omi, adenylate kinase-2, or apoptosis-inducing factor.
  • the BH3 domain peptide is derived from the BH3 domain of a BID, a BIM, a BAD, a NOXA, a PUMA, a BMF, or an HRK polypeptide. In some embodiments, the BH3 domain peptide is selected from the group consisting of SEQ ID NO: 1-16.
  • the agent comprises one or more compounds.
  • the agent is an anticancer agent.
  • the agent is a chemotherapeutic agent.
  • the agent is a small organic molecule, small inorganic molecule, peptide, protein, protein analog, enzyme, nucleic acid, nucleic acid analog, antibody, antigen, hormone, lipid, polysaccharide, growth factor, virus, cell, bioactive agent, pharmaceutical agent, or some combination or prodrug thereof.
  • the agent is gas, fine particles, radiation, electromagnetic radiation, or aerosol.
  • the disclosure provides a method of predicting toxicity of an agent, said method comprising: a) providing one or more cell samples, wherein each cell sample comprises non-cancerous cells and was obtained from a tissue from a non-human animal that had been contacted with a sublethal dose of an agent and then sacrificed; b) providing a test aliquot of each of the one or more cell samples; c) separately contacting each test aliquot with the agent; d) providing a control aliquot of each of the one or more cell samples, wherein the control aliquot is not contacted with the agent; e) permeabilizing the cells in each aliquot; f) contacting the permeabilized cells with a pro-apoptotic BH3 domain peptide; g) determining a value for percent BH3 domain peptide-induced MOMP in the cells in the test aliquot; h) determining a value for percent BH3 domain peptide-induced MOMP in the cells in the control aliquot; and
  • the non-human animal is a mammal.
  • the mammal is a non-human primate or a rodent.
  • the non-human animal is contacted with the agent by injection, inhalation, topical administration, or oral administration. In some embodiments, the non-human animal is contacted with the agent for 24 hours or less.
  • the permeabilized cells are contacted with the pro-apoptotic BH3 domain peptide for 3 hours or less.
  • the cells are permeabilized with digitonin or saponin.
  • the percent BH3 domain peptide-induced MOMP is determined by one or more of: i) contacting the cells with a potentiometric dye and measuring the emission of said potentiometric dye; ii) measuring the release of a molecule from the mitochondrial intermembrane space; and iii) measuring the retention of a molecule from the mitochondrial intermembrane space.
  • the potentiometric dye is 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1), dihydrorhodamine 123, tetramethylrhodamine methyl ester (TMRM), or tetramethylrhodamine ethyl ester (TMRE).
  • the molecule from the mitochondrial intermembrane space is cytochrome c, SMAC/Diablo, Omi, adenylate kinase-2, or apoptosis-inducing factor.
  • the BH3 domain peptide is derived from the BH3 domain of a BID, a BIM, a BAD, a NOXA, a PUMA, a BMF, or an HRK polypeptide. In some embodiments, the BH3 domain peptide is selected from the group consisting of SEQ ID NO: 1-16.
  • the agent comprises one or more compounds.
  • the agent is an anticancer agent.
  • the agent is a chemotherapeutic agent.
  • the agent is a small organic molecule, small inorganic molecule, peptide, protein, protein analog, enzyme, nucleic acid, nucleic acid analog, antibody, antigen, hormone, lipid, polysaccharide, growth factor, virus, cell, bioactive agent, pharmaceutical agent, or some combination or prodrug thereof.
  • the agent is gas, fine particles, radiation, electromagnetic radiation, or aerosol.
  • the cells are cultured on an adhesive solid surface in a culture medium having serum in the presence and absence of an agent. In some embodiments of any of the provided methods, the method further comprises washing the culture media from the cells prior to contacting the cells with the BH3 profiling buffer and the pro-apoptotic BH3 domain peptide.
  • the BH3 profiling buffer is added at a concentration of 2X, 3X or 4X. In some embodiments, the BH3 profiling buffer is added at a concentration of 2X and the amount of BH3 domain peptide induced MOMP is measured by microscopy. In some embodiments, the BH3 profiling buffer is added at a concentration of 3X or 4X and the amount of BH3 domain peptide induced MOMP is measured by Fluorescence-activated cell sorting (FACS).
  • FACS Fluorescence-activated cell sorting
  • the adhesive solid surface is coated with one or more pro-adhesive compounds.
  • the one or more pro-adhesive compounds is an extracellular matrix (ECM) protein.
  • ECM extracellular matrix
  • the ECM protein is selected from the group consisting of collagen 1, laminin, collagen 4 and fibronectin.
  • the one or more pro-adhesive compounds is an antibody.
  • the one or more pro-adhesive compounds is streptavidin.
  • the BH3 profiling buffer is Derived from Trehalose Experimental Buffer (DTEB) or Mitochondria Experimental Buffer (MEB).
  • the cells are permeabilized after, prior to, or simultaneously when contacting with the BH3 domain peptide.
  • the BH3 profiling buffer is supplemented with a permeabilizing agent.
  • the permeabilizing agent is digitonin or saponin.
  • Dynamic BH3 profiling is a technique used to measure the sensitivity of cells to a test compound or therapeutic. This technique has been described previously in WO 2014/047342 and WO 2015/010094 .
  • the present disclosure relates to the discovery that the principles of dynamic BH3 profiling can be utilized to assess the toxicity of an agent in non-cancerous cells.
  • the disclosure provides methods for quickly and effectively determining how an agent alters the apoptotic sensitivity of non-cancerous cells.
  • many current means of assessing drug toxicity during drug development is limited because pre-clinical toxicity largely relies on testing in mammals, which can be expensive, time consuming, and unreliable.
  • Dynamic BH3 profiling methods provided herein provide inexpensive and robust alternatives to traditional pre-clinical toxicity testing.
  • dynamic BH3 profiling may be carried out on normal cells, e.g., a panel of normal cells, to perform toxicity screens of drugs on normal primary tissues.
  • Dynamic BH3 profiling methods permit profiling of normal cells to rapidly detect the presence of toxic agents (e.g., radiation, gas, biological agents, etc. ) in an environment.
  • toxic agents e.g., radiation, gas, biological agents, etc.
  • the disclosure provides a method of screening a plurality of agents for determining toxicity, including: a) providing a plurality of agents; b) providing a test aliquot of the sample of cells for each of the plurality of agents, wherein the sample of cells are non-cancerous cells obtained from a subject; c) separately contacting each test aliquot with its respective agent; d) providing a control aliquot of the sample of cells, wherein the control aliquot is not contacted with any of the plurality of agents; e) permeabilizing the cells in each aliquot; f) contacting the permeabilized cells with a pro-apoptotic BH3 domain peptide; g) determining a value for percent BH3 domain peptide-induced MOMP in the cells in each of the test aliquots; h) determining a value for percent BH3 domain peptide-induced MOMP in the cells in the control aliquot; and i) determining a value for delta percent priming for each of
  • the disclosure provides a method of predicting toxicity of an agent to a tissue, said method comprising: a) providing an agent; b) providing a test aliquot of each of a plurality of cell samples, wherein each cell sample comprises non-cancerous cell obtained from a tissue of a subject; c) separately contacting each test aliquot with the agent; d) providing a control aliquot of each of the plurality of cell samples, wherein the control aliquot is not contacted with the agent ( e.g., the control aliquot contains cells not contacted with the agent or contains cells from an animal not contacted with the agent); e) permeabilizing the cells in each test aliquot and control aliquot; f) contacting the permeabilized cells with a pro-apoptotic BH3 domain peptide; g) determining a value for percent BH3 domain peptide-induced MOMP in the cells in each test aliquot; h) determining a value for percent BH3 domain peptide
  • the non-cancerous cells are normal healthy cells (e.g., cells that do not have any patent or latent pathological condition).
  • the non-cancerous cells are infected with an infectious agent, e.g., a virus or an intracellular bacterium.
  • the non-cancerous cells are from an organ that is otherwise not functioning normally.
  • the non-cancerous cells are subject to stress, e.g., vascular stress such as hypoxia, stroke, myocardial infarction, among others.
  • the cells are mammalian cells.
  • the cells are derived from samples obtained by biopsy or autopsy of an animal.
  • the cells are non-malignant human or mouse primary cells.
  • provided methods further include j) providing a test aliquot of a sample of cancerous cells obtained from a subject for each of the plurality of agents; k) separately contacting each test aliquot with its respective agent; 1) providing a control aliquot of the sample of cancerous cells, wherein the control aliquot is not contacted with any of the plurality of agents; m) permeabilizing the cancerous cells in each aliquot; n) contacting the permeabilized cancerous cells with a pro-apoptotic BH3 domain peptide; o) determining a value for percent BH3 domain peptide-induced MOMP in the cancerous cells in each of the test aliquots; p) determining a value for percent BH3 domain peptide-induced MOMP in the cancerous cells in the control aliquot; and q) determining a value for delta percent priming for each of the test aliquots, wherein delta percent priming is the difference between the value for percent MOMP determined in (o) and the value
  • the method further comprises conducting in vivo toxicity testing with the agent in a non-human animal or in vitro toxicity testing with the agent if the delta percent priming in the cancerous cells is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, or at least 200%, greater than the delta percent priming in the non-cancerous cells.
  • the method further comprises conducting in vivo toxicity testing with the agent in a non-human animal or in vitro toxicity testing with the agent if the delta percent priming in the cancerous cells is at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold greater than the delta percent priming in the non-cancerous cells.
  • the cancerous cells comprise an immortalized cancer cell line.
  • the cells are immortalized mouse or human cancer cell lines.
  • Established cancer cell lines are well-known in the art and include for example pancreatic cancer cell lines (e.g., YAPC, Panc02.03 and SU86.86, etc. ), breast cancer cell lines (e.g., AU565, BT-20, CAL-120, HMEL and KPL-1, etc. ), kidney cancer lines ( e.g., 769-P, ACNH, HEK TE, SLR 20 and UMRC2, etc. ), bone cancer cell lines ( e.g., CAL-78, HOS, MG-63 and SK-ES-1, etc.
  • pancreatic cancer cell lines e.g., YAPC, Panc02.03 and SU86.86, etc.
  • breast cancer cell lines e.g., AU565, BT-20, CAL-120, HMEL and KPL-1, etc.
  • kidney cancer lines e.g., 7
  • lymphoid cancer cell lines e.g., AML-193, BDCM, CML-T1 and JM1, etc.
  • lymphoid cancer cell lines e.g., AML-193, BDCM, CML-T1 and JM1, etc.
  • the skilled artisan recognizes other cancer cell lines, for example those disclosed in Barretina et al. (The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012 Mar 28;483(7391):603-7. doi: 10.1038/nature11003 ).
  • the cells are derived from a subject.
  • cancer cells may be isolated from a subject by a surgical technique (e.g., biopsy).
  • the cells are primary tumor cells.
  • the cells comprise a patient-derived xenograft (PDX).
  • PDX patient-derived xenograft
  • the term "patient-derived xenograft" (PDX) refers to tissue generated by the implantation of cancerous primary tumor into an immunodeficient mouse.
  • contacting the cells includes culturing the cells in the presence or absence of an agent.
  • the cells are cultured in a culture medium under suitable culture conditions in the presence or absence of an agent.
  • a "culture medium” (also referred to herein as a "cell culture medium” or “medium”) is a medium for culturing cells containing nutrients that maintain cell viability and support proliferation.
  • the disclosure contemplates various parameters and conditions for culturing the cell.
  • the culture medium contains serum.
  • the cell culture medium may contain any of the following nutrients in appropriate amounts and combination: salt(s), buffer(s), amino acids, glucose or other sugar(s), antibiotics, serum or serum replacement, and other components such as peptide growth factors, etc.
  • Cell culture media are known in the art and may be classified as natural or artificial media. Examples of cell culture media include but are not limited to Minimum Essential Medium (MEM), Dulbecco's Modified Eagle's Medium (DMEM) and Roswell Park Memorial Institute Medium (RPMI). Selection of an appropriate medium for culturing the cell is within the capability of the skilled artisan. Suitable conditions include growing the cell under standard cell culture conditions in a cell culture incubator (e.g., at 37° C in a humidified atmosphere of >80% relative humidity air and 5 to 10% CO 2 ).
  • MEM Minimum Essential Medium
  • DMEM Dulbecco's Modified Eagle's Medium
  • RPMI Roswell Park Memorial Institute Medium
  • the cells are contacted with an agent, e.g., cultured in the presence of an agent, for at least 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, 1 day, at least 2 days, at least 3 days, or at least 4 days.
  • the cells are contacted with an agent, e.g., cultured in the presence of an agent, for 48 hours or less, 36 hours or less, 24 hours or less, or 12 hours or less.
  • the disclosure provides a method of predicting toxicity of an agent, said method comprising: a) contacting a non-human animal with a sublethal dose of an agent; b) sacrificing the animal; c) providing one or more cell samples, wherein each cell sample comprises non-cancerous cells and was obtained from a tissue from the animal; d) providing a test aliquot of each of the one or more cell samples; e) separately contacting each test aliquot with the agent; f) providing a control aliquot of each of the one or more cell samples, wherein the control aliquot is not contacted with the agent; g) permeabilizing the cells in each aliquot; h) contacting the permeabilized cells with a pro-apoptotic BH3 domain peptide; i) determining a value for percent BH3 domain peptide-induced MOMP in the cells in the test aliquot; j) determining a value for percent BH3 domain peptide-induced MOMP in the cells in the cells in the
  • a subject is preferably a mammal.
  • the mammal is, for example, a human, non-human primate, mouse, rat, dog, cat, horse, or cow.
  • the mammal is a non-human primate or a rodent.
  • the subject is a genetically-modified animal.
  • a mouse can be genetically engineered to develop a particular cancer.
  • the subject has not been previously diagnosed as having cancer.
  • the subject has been previously diagnosed as having cancer, and possibly has already undergone treatment for cancer.
  • aspects of the disclosure can relate to contacting a subject (e.g., a non-human animal) with a sublethal dose of an agent.
  • a subject e.g., a non-human animal
  • the non-human animal can be contacted with the agent by methods known in the art.
  • the agent is administered to the animal, e.g., by injection, inhalation, topical administration, or oral administration.
  • the agent can be administered by topical administration (e.g., epicutaneous or inhalational administration), enteral administration (e.g., oral, gastric, or rectal administration), or parenteral administration (e.g., intravenous, intra-arterial, intraosseous, intra-muscular, intracerebral, intracerebroventricular, intrathecal, or subcutaneous administration).
  • topical administration e.g., epicutaneous or inhalational administration
  • enteral administration e.g., oral, gastric, or rectal administration
  • parenteral administration e.g., intravenous, intra-arterial, intraosseous, intra-muscular, intracerebral, intracerebroventricular, intrathecal, or subcutaneous administration.
  • Cell sensitivity to the agent is determined by contacting the cells or cellular component (e.g., mitochondria) with a BH3 profiling buffer and a BH3 domain peptide from the pro-apoptotic BCL-2 family or small molecules with direct mitochondrial activity. This includes, but is not limited to ABT-199, ABT-263, ABT-737, WEHI-539, A-1210477, and ABT-199.
  • the ability of BH3 peptides to induce MOMP is measured in the cells (or cellular component, e.g., mitochondria) exposed to the agent and the control cells (or cellular component, e.g., mitochondria) not exposed to the agent.
  • An increase in BH3 peptide-induced MOMP in the cells cultured in the presence of the agent compared to the amount of BH3 domain peptide induced MOMP in the cells cultured in the absence of the agent indicates that the cells are responsive ( e.g., cell death will be induced) to the agent.
  • No change in MOMP in the cells cultured in the presence of the agent compared to the amount of BH3 domain peptide induced MOMP in the cells cultured in the absence of the agent indicates that the drug has no effect on inducing cell death.
  • a decrease in MOMP in the cells cultured in the presence of the agent compared to the amount of BH3 domain peptide induced MOMP in the cells cultured in the absence of the agent indicates that the agent has a desensitizing or protective effect on the cells.
  • the difference in the level of BH3 domain peptide-induced MOMP of cells that have been exposed to the agent as compared to the level of BH3 domain peptide-induced MOMP of cells that have not been exposed to the agent is statistically significant.
  • statistically significant it is meant that the alteration is greater than what might be expected to happen by chance alone.
  • Significant differences may be identified by using an appropriate statistical test. Tests for statistical significance are well known in the art and are exemplified in Applied Statistics for Engineers and Engineers by Petruccelli, Chen and Nandram 1999 Reprint Ed .
  • BH3 Profiling Buffer refers to an aqueous solution comprising a sugar, a pH buffer, salts, chelators and a carbon source for the electron transport chain that is useful for performing measurements of MOMP.
  • Pro-apoptotic BCL-2 BH3 proteins and peptides include: Bcl-2 interacting mediator of cell death (BIM); a mutant thereof (BIM AV); BH3 interacting domain death agonist (BID); Bcl-2-associated death promoter (BAD); NOXA; p53 up-regulated modulator of apoptosis (PUMA); Bcl-2-modifying factor (BMF) and harakiri (HRK) (See, Table 1).
  • the method comprises permeabilizing the cell after, prior to, or simultaneously when contacting with the BH3 domain peptide.
  • permeabilization refers to the process of treating a cell with a reagent such that the cell membrane becomes permeable without permeabilizing the mitochondrial outer membrane.
  • Reagents used for permeabilization include organic solvents (e.g., acetone and methanol) and detergents (e.g., digitonin, saponin, Triton X-100 and Tween-20).
  • the cell is permeabilized to permit the BH3 peptides access to the mitochondria.
  • Cells are permeabilized by methods known in the art.
  • the cell are permeabilized by contacting the cell with digitonin, saponin, methanol, Triton X-100 or other art-recognized cell-permeabilization agents.
  • the BH3 profiling buffer comprises the permeabilizing reagent, such as digitonin or saponin.
  • permeabilized cells are contacted with the pro-apoptotic BH3 domain peptide for 3 hours or less, 2 hours or less, or 1 hour or less.
  • automated liquid handling systems are generally utilized for high throughput drug screening.
  • Automated liquid handling systems utilize arrays of liquid dispensing vessels, controlled by a robotic arm, to distribute fixed volumes of liquid to the wells of an assay plate. Generally, the arrays comprise 96, 384 or 1536 liquid dispensing tips.
  • Non-limiting examples of automated liquid handling systems include digital dispensers (e.g., HP D300 Digital Dispenser) and pinning machines (e.g., MULTI-BLOT TM Replicator System, CyBio, Perkin Elmer Janus).
  • Non-automated methods are also contemplated by the disclosure, and include but are not limited to a manual digital repeat multichannel pipette.
  • Outer membrane permeabilization can be measured in several ways. For example, outer membrane permeabilization can be measured by determining the loss of mitochondrial membrane potential. Loss of mitochondrial membrane potential is measured by, for example, treating the cells with a potentiometric or radiometric dye.
  • potentiometric dyes include, but are not limited to, the fluorescent JC-1 probe (5,5',6,6'-tetrachloro-l,l',3,3'-tetraethylbenzimidazolylcarbocyanine iodide) or dihydrorhodamine 123, or tetramethylrhodamine methyl ester (TMRM) or tetramethylrhodamine ethyl ester (TMRE). These and other potentiometric dyes are well-known in the art.
  • the fluorescent JC-1 probe (5,5',6,6'-tetrachloro-l,l',3,3'-tetraethylbenzimidazolylcarbocyanine iodide) or dihydrorhodamine 123, or tetramethylrhodamine methyl ester (TMRM) or tetramethylrhodamine ethyl ester (TMRE).
  • outer membrane permeabilization is determined by measuring the release of a molecule from the mitochondrial intermembrane space or by measuring the retention of a molecule from the mitochondrial intermembrane space.
  • a molecule from the mitochondrial intermembrane space examples include cytochrome c, SMAC/Diablo, Omi, adenylate kinase-2, or apoptotic-inducing factor (AIF).
  • AIF apoptotic-inducing factor
  • the release or retention of a molecule from the mitochondrial intermembrane space can be measured by methods well-known in the art.
  • the release or retention of a molecule can be measured by using an antibody to the molecule, i.e., an antibody to cytochrome c, SMAC/Diablo, Omi, adenylate kinase-2 or apoptotic-inducing factor (AIF).
  • Detection can be for example, by ELISA, FACS, immunoblot, immunofluorescence, immunohistochemistry, plate fluorimetry, fluorescent imaging or automated image analysis. Analysis of the cells can be manually accomplished using a microscope or automated for example by using software such as Cellprofiler to locate nuclei.
  • the cells are fixed prior to measuring outer membrane permeabilization.
  • Cells are fixed by methods known in the art, such as by using an aldehyde (e.g., formaldehyde), or methanol.
  • aldehyde e.g., formaldehyde
  • methanol e.g., methanol
  • Mitochondrial outer membrane permeabilization can be measured at the single cell level or multi-cell level. Additionally, some of the methods disclosed herein allow for subpopulations of cells to be assayed. For example, a tumor-specific or tumor-associated marker (e.g., EpCam) can be used to identify tumor cells. This allows for the ability to discriminate between normal and tumor cells. MOMP is then measured as described herein in the tumor cells.
  • a tumor-specific or tumor-associated marker e.g., EpCam
  • measurements of MOMP can be normalized to facilitate comparative assessments.
  • some aspects of the methods provided herein relate to screening a plurality of agents for determining toxicity by determining BH3 domain peptide-induced MOMP in a cell for each of the plurality of agents.
  • BH3 domain peptide-induced MOMP can be measured by methods known in the art. Normalization of measured BH3 peptide-induced MOMP can be performed by methods known in the art, such as described in Ryan, J., Letai, A. (2013) Methods 61(2): 156-164 and Friedman, A., Letai, A., Fisher, D., Flaherty, K. (2015) Nature Reviews Cancer 15: 747-756 .
  • the control aliquot is contacted with a pro-apoptotic BH3 domain peptide.
  • the BH3 domain peptide-induced MOMP in these "untreated” cells is measured as described herein and by methods known in the art.
  • the measured MOMP in "treated” and “untreated” cells can be compared by measuring a maximum range for MOMP measurements in a given sample of cells.
  • the maximum range for MOMP measurements can be determined by measuring an "upper limit” value for MOMP and a "lower limit” value for MOMP.
  • an "upper limit” value for MOMP measurements can be obtained by contacting a separate aliquot of the sample of cells with a molecule that is known to be toxic to a cell and measuring a value for MOMP.
  • the molecule that is known to be toxic to a cell is an uncoupling agent such as carbonyl cyanide- p -trifluoromethoxyphenylhydrazone (FCCP) or carbonyl cyanide m -chlorophenyl hydrazine (CCCP).
  • FCCP carbonyl cyanide- p -trifluoromethoxyphenylhydrazone
  • CCCP carbonyl cyanide m -chlorophenyl hydrazine
  • a "lower limit" value for MOMP measurements can be obtained by measuring a value for MOMP in a separate aliquot of cells that have not been contacted with an agent, a pro-apoptotic BH3 domain peptide, or a molecule that is known to be toxic to a cell.
  • methods provided herein relate to determining the toxicity of an agent in a sample of cells.
  • the toxicity of the agent can be determined by determining a value for delta percent priming.
  • delta percent priming refers to the extent to which an agent shifts a cell closer to the threshold of apoptosis.
  • normalized values of MOMP e.g., percent BH3 domain peptide-induced MOMP, or "% MOMP " are used to determine a value for delta percent priming.
  • Determining a value for delta percent priming can provide an assessment of the toxicity attributable to a particular agent in a given sample of cells. As described herein, the greater the value for delta percent priming of a cell contacted with an agent, the greater the toxicity of the agent to the cell. Thus, in some embodiments, the toxicity of a first agent in a sample of cells can be compared to the toxicity of a second agent in the sample of cells by comparing the value for delta percent priming determined for each agent. Such methods can be useful to screen for agents that are more toxic to a given sample of cells or less toxic to a given sample of cells, depending upon the outcome desired by a practitioner.
  • methods provided herein relate to determining the toxicity of an agent in each of a plurality of cell samples.
  • the toxicity of the agent in a first cell sample can be compared to the toxicity of the agent in a second cell sample by comparing the value for delta percent priming determined for the agent in each of the cell samples.
  • Such methods can be useful to assess the toxicity of a given agent across different cell types (e.g., cells obtained from different tissue types).
  • the disclosure provides methods for determining the toxicity of an agent to a sample of cells, wherein the cells are non-cancerous.
  • a delta percent priming of greater than 20% indicates that the agent is toxic to the non-cancerous cells.
  • a delta percent priming of greater than 0% indicates that the agent is toxic to the non-cancerous cells.
  • methods provided herein further comprise conducting in vivo toxicity testing with agent in a non-human animal or in vitro toxicity testing with the agent if the delta percent priming in the non-cancerous cells is 20% or less.
  • in vivo or in vitro toxicity testing is conducted with an agent if the delta percent priming in the non-cancerous cells is 20% or less, 18% or less, 16% or less, 14% or less, 12% or less, 10% or less, 8% or less, 6% or less, 5% or less, 4% or less, 3% or less, 2% or less, 1% or less, 0.9% or less, 0.8% or less, 0.7% or less, 0.6% or less, 0.5% or less, 0.4% or less, 0.3% or less, 0.2% or less, 0.1% or less, or 0%.
  • aspects of the disclosure provide methods relating to determining toxicity of an agent in a sample of non-cancerous cells.
  • methods provided herein can further comprise steps relating to determining toxicity of the agent in a sample of cancerous cells.
  • the toxicity of the agent in the cancerous cells can be assessed using methods provided herein, for example, by determining a value for delta percent priming.
  • a delta percent priming of greater than 20% indicates that the agent is toxic to the cancerous cells.
  • a delta percent priming of greater than 0% indicates that the agent is toxic to the cancerous cells.
  • methods provided herein further comprise conducting in vivo toxicity testing with the agent in a non-human animal or in vitro toxicity testing with the agent if the delta percent priming in the cancerous cells is greater than 20%.
  • in vivo toxicity testing with the agent in a non-human animal or in vitro toxicity testing is conducted with an agent if the delta percent priming in the cancerous cells is greater than 20%, greater than 25%, greater than 30%, greater than 35%, greater than 40%, greater than 45%, greater than 50%, greater than 55%, greater than 60%, greater than 65%, greater than 70%, greater than 75%, greater than 80%, greater than 85%, greater than 90%, greater than 95%, greater than 98%, greater than 99%, or 100%.
  • methods provided herein further comprise conducting in vivo toxicity testing with the agent in a non-human animal or in vitro toxicity testing with the agent if the delta percent priming in the non-cancerous cells is lower than the delta percent priming in the cancerous cells.
  • in vivo or in vitro toxicity testing can comprise methods provided herein and methods known in the art related to determining the toxicity of an agent.
  • certain aspects of the disclosure relate to the screening of a plurality of agents for determining toxicity in a sample of non-cancerous cells.
  • the agent can be selected for further toxicity testing (e.g., in vivo or in vitro toxicity testing).
  • it can be useful to conduct further testing comprising determining the toxicity of the agent in a different sample of cells (e.g., cancerous cells, cells obtained from a different type of tissue, cells obtained from a different subject).
  • it can be useful to conduct further testing comprising determining the toxicity of the agent in a subject ( e.g., by administering the agent to the subject, by contacting the agent with a sample of cells obtained from the subject).
  • an agent e.g., a therapeutic agent, a cancer therapeutic
  • an agent e.g., a therapeutic agent, a cancer therapeutic
  • such an agent would manifest as having a minimal value for delta percent priming in non-cancerous cells and a maximal value for delta percent priming in cancerous cells.
  • the disclosure relates to drug discovery.
  • methods described by the disclosure are useful for screening large libraries of candidate agents to identify new drugs that do not move cells closer to programmed cell death, e.g., agents that are not toxic to the cells.
  • the library of candidate agents includes 20 or more, 30 or more, 40 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, 100 or more, 150 or more, 200 or more, 250 or more, or 300 or more agents.
  • an agent includes a compound. In some embodiments, an agent includes more than one compound.
  • Exemplary candidate agents include, but are not limited to small organic molecules, small inorganic molecules, peptides, proteins, protein analogs, enzymes, nucleic acids, nucleic acid analogs, antibodies, antigens, hormones, lipids, polysaccharides, growth factors, viruses, cells, bioactive agents, pharmaceutical agents, and combinations and prodrugs thereof.
  • an agent is an anticancer agent, such as, a chemotherapeutic agent.
  • Further exemplary candidate agents include, but are not limited to, gases, fine particles, radiation, electromagnetic radiation, and aerosols.
  • a candidate agent is a chemotherapeutic agent.
  • chemotherapeutic agents include small molecules, peptides or proteins (e.g., peptide antibiotics and antibodies) and RNA-interference (RNAi) molecules.
  • small molecule chemotherapeutic agents include alkylating agents (cyclophosphamide, chlormethine, temozolomide), anthracyclines (daunorubicin, doxorubicin, mitoxantrone), taxanes (paclitaxel, docetaxel), histone deacetylase inhibitors (vorinostat, romidepsin), topoisomerase I/II inhibitors (irinotecan, topotecan, etoposide), kinase inhibitors (gefitinib, imatinib, bortezomib), nucleotide analogs and precursor analogs (azacitidine, fluorouracil, methotrexate), platinum-based agents (cisplatin, carboplatin), retinoids (alitretinoin, bexarotene) and vinca alkaloids (vinblastine, vindesine, vinorelbine).
  • alkylating agents cyclophos
  • RNAi molecules examples include bleomycin, dactinomycin, antitumor antibodies (anti-HER2/neu, alemtuzumab, trastuzumab, brentuximab).
  • chemotherapeutic RNAi molecules as RNAi molecules that target expression of genes related to cancer.
  • RNAi molecules directed against Hox A1 can inhibit mammary tumor cell formation, as disclosed by Brock et al. Sci Transl Med 6: 217ra2 (2014 ).
  • chemotherapeutic agents include, but are not limited to, kinase inhibitors, apoptosis inducers, angiogenesis inhibitors, and monoclonal antibodies.
  • methods provided herein can be useful for determining the toxicity of an environment or environmental condition.
  • the environment comprises an agent that may or may not be toxic to a cell.
  • agents in an environment or environmental condition can include, without limitation, gases, fine particles, radiation, electromagnetic radiation, and aerosols.
  • Environmental agents are known in the art, for example, as provided by the National Institute of Environmental Health Sciences (www.niehs.nih.gov/health/topics/agents/).
  • cells can be contacted with the agent using various methods known in the art and described herein.
  • a cell can be exposed to an environment that is suspected of being radioactive or known to be radioactive.
  • the agent being tested for toxicity could comprise radiation (e.g., alpha particles, beta particles, positron particles, gamma rays, X-rays, and neutrons).
  • the disclosure relates to personalized medicine.
  • methods described herein are useful for the customization of chemotherapeutic regimens.
  • methods provided herein can relate to determining the toxicity of an agent in both non-cancerous cells and cancerous cells.
  • the non-cancerous cells and the cancerous cells are obtained from a subject. By determining the toxicity of the agent in non-cancerous cells (e.g., normal cells, healthy cells) from the subject and determining the toxicity of the agent in cancerous cells from the subject, the agent can be identified as being more or less appropriate for treating the subject.
  • the agent becomes more appropriate for treating the subject as the ratio of delta percent priming in cancerous cells to delta percent priming in non-cancerous cells increases.
  • an agent that has minimal toxicity (e.g., minimal value for delta percent priming) in non-cancerous cells of the patient and maximal toxicity (e.g., maximal value for delta percent priming) in cancerous cells of the patient.
  • minimal toxicity e.g., minimal value for delta percent priming
  • maximal toxicity e.g., maximal value for delta percent priming
  • the disclosure provides methods of determining the toxicity of an agent, wherein the toxicity of the agent is determined by comparing BH3 domain peptide-induced MOMP in test cells contacted with the agent to BH3 domain peptide-induced MOMP to control cells not contacted with the agent.
  • the control cells have not been contacted with any agent.
  • the control cells have been contacted with buffer or solvent, e.g., buffer or solvent used as a vehicle for the agent.
  • the test cells can be contacted with an agent that has been dissolved in a suitable buffer or solvent (e.g., DMSO), and the control can be contacted with a suitable buffer or solvent (e.g., DMSO) lacking the agent.
  • methods described herein can be suitable for a high-throughput format.
  • aspects of the disclosure relate to methods of screening of a plurality of agents to determine toxicity.
  • the plate comprises an agent.
  • the plate comprises a plurality of agents.
  • the plate may be used to test a panel of agents, each well comprising an agent.
  • one or more wells of the plate do not comprise an agent.
  • control aliquots are not contacted with an agent.
  • one or more wells designated for control aliquots can comprise buffer or solvent (e.g., DMSO).
  • the multi-well plate comprises a BH3 domain peptide.
  • the BH3 domain peptide is derived from the BH3 domain of a BID, a BIM, a BAD, a NOXA, a PUMA a BMF, or a HRK polypeptide.
  • the BH3 domain peptide is selected from the group consisting of SEQ ID NO: 1-15.
  • the plate comprises more than one BH3 domain peptide.
  • a plate comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10 BH3 domain peptides.
  • one or more wells of the plate do not comprise a BH3 domain peptide.
  • a BH3 domain peptide For example, as described herein, it may be desirable to establish a lower limit for MOMP measurements. In such embodiments, aliquots are not contacted with a BH3 domain peptide.
  • one or more wells designated for lower limit measurements can comprise buffer or solvent (e.g., DMSO).
  • the cells do not need to be removed from a culture plate to perform dynamic BH3 profiling described herein.
  • the presence of cell culture media and serum has been demonstrated not to interfere with the ability of BH3 peptides to induce mitochondrial outer membrane permeabilization.
  • wash steps where there is little residual volume above the cells have been demonstrated to be unnecessary. Instead, the cells can be successively treated in the plate well with the drug and the BH3 domain peptide.
  • the cells are cultured on an adhesive solid surface in a culture medium having serum in the presence and absence of an agent.
  • the method further comprises washing the culture media from the cells prior to contacting the cells with the BH3 profiling buffer and the pro-apoptotic BH3 domain peptide.
  • the adhesive solid surface is coated with one or more pro-adhesive compounds.
  • the one or more pro-adhesive compounds is an extracellular matrix (ECM) protein.
  • ECM extracellular matrix
  • the ECM protein is selected from the group consisting of collagen 1, laminin, collagen 4 and fibronectin.
  • the one or more pro-adhesive compounds is an antibody.
  • the one or more pro-adhesive compounds is streptavidin.
  • the BH3 profiling buffer is Derived from Trehalose Experimental Buffer (DTEB) or Mitochondria Experimental Buffer (MEB).
  • the cells are permeabilized after, prior to, or simultaneously when contacting with the BH3 domain peptide.
  • the BH3 profiling buffer is supplemented with a permeabilizing agent.
  • the permeabilizing agent is digitonin or saponin
  • the term "BH3 Profiling Buffer” refers to an aqueous solution comprising a sugar, a pH buffer, salts, chelators and a carbon source for the electron transport chain that is useful for performing measurements of MOMP.
  • the BH3 Profiling Buffer is a Derived from Trehalose Experimental Buffer (DTEB).
  • the BH3 Profiling Buffer is a Mitochondria Experimental Buffer (MEB).
  • DTEB is comprised of 135 mM trehalose, 10 mM Hepes, 50 mM KCl, 20 ⁇ M EGTA, 20 ⁇ M EDTA, 0.1 % BSA and 5mM Succinate.
  • MEB is comprised of 150 mM mannitol, 10 mM Hepes, 50 mM KCl, 20 ⁇ M EGTA, 20 ⁇ M EDTA, 0.1 % BSA and 5mM Succinate. Sucrose and other sugars may be used in the place of mannitol. Some increases in KCl are tolerated, however can be detrimental to BH3 profiling. Concentrated buffers (2X-5X) involve proportionally increasing the concentration of the above reagents
  • the BH3 profiling buffer is added at a concentration of 2X, 3X or 4X. In some embodiments of any of the provided methods, the BH3 profiling buffer is added at a concentration of 2X and the amount of BH3 domain peptide induced MOMP is measured by microscopy. In some embodiments of any of the provided methods, the BH3 profiling buffer is added at a concentration of 3X or 4X and the amount of BH3 domain peptide induced MOMP is measured by Fluorescence-activated cell sorting (FACS).
  • FACS Fluorescence-activated cell sorting
  • automated liquid handling systems are generally utilized for high throughput drug screening.
  • Automated liquid handling systems utilize arrays of liquid dispensing vessels, controlled by a robotic arm, to distribute fixed volumes of liquid to the wells of an assay plate. Generally, the arrays comprise 96, 384 or 1536 liquid dispensing tips.
  • Non-limiting examples of automated liquid handling systems include digital dispensers (e.g., HP D300 Digital Dispenser) and pinning machines (e.g., MULTI-BLOT TM Replicator System, CyBio, Perkin Elmer Janus).
  • Non-automated methods are also contemplated by the disclosure, and include but are not limited to a manual digital repeat multichannel pipette.
  • Pro-Apoptotic BCL-2 BH3 domain peptides have been described previously in WO 2014/047342 .
  • a Pro-apoptotic BCL-2 BH3 domain peptide is less than 195 amino acids in length, e.g., less than or equal to 150, 100, 75, 50, 35, 25 or 15 amino acid in length.
  • Non-limiting examples of pro-apoptotic BCL-2 BH3 peptides include: Bcl-2 interacting mediator of cell death (BIM); a mutant thereof (BIM AV); BH3 interacting domain death agonist (BID); Bcl-2-associated death promoter (BAD); NOXA; p53 up-regulated modulator of apoptosis (PUMA); Bcl-2-modifying factor (BMF) and harakiri (HRK).
  • a pro-apoptotic BCL-2 BH3 domain peptide includes the sequence of SEQ ID NO: 1-15 shown in Table 1.
  • PUMA2A (SEQ ID NO: 16) is a negative control peptide.
  • Table 1 Pro-Apoptotic Peptide Sequence SEQ ID NO: BIM Ac-MRPEIWIAQELRRIGDEFNA-NH2 1 BIM AC AC-MRPEIWIAQELRRIGDEFNV-NH2 2 BID EDIIRNIARBLAQ VGD SMDR 3 BIM AV MRPEIWIAQELRRIGDEFNA 4 BID mut EDIIRNIARHAAQVGASMDR 5 BAD LWAAQRYGRELRRMSDEFEGSFKGL 6 BIK MEGSDALALRLACIGDEMDV 7 NOXA A AELPPEFAAQLRKIGDKVYC 8 NOXA B PADLKDECAQLRRIGDKVNL 9 HRK S S AAQLTAARLKALGDELHQ 10 PUMA EQW
  • a BH3 domain peptide include a peptide which includes (in whole or in part) the sequence NH 2 -XXXXXXXXXLXXXDXXXX -COOH (SEQ ID NO: 17).
  • X may be any amino acid.
  • the BH3 domain peptides include at least 5, 6, 7, 8, 9, 15 or more amino acids of SEQ ID NO: 17.
  • the BH3 domain peptides can be modified using standard modifications. Modifications may occur at the amino (N-), carboxy (C-) terminus, internally or a combination of any of the preceding. In one aspect described herein, there may be more than one type of modification on the polypeptide. Modifications include but are not limited to: acetylation, amidation, biotinylation, cinnamoylation, farnesylation, formylation, myristoylation, palmitoylation, phosphorylation (Ser, Tyr or Thr), stearoylation, succinylation, sulfurylation and cyclisation (via disulfide bridges or amide cyclisation), and modification by Cys3 or Cys5.
  • the modified BH3 domain peptides retain the biological activity of BH3 domain peptides.
  • retaining the biological activity it is meant that cell death is induced by the BH3 polypeptide, although not necessarily at the same level of potency as that of the naturally-occurring BH3 domain polypeptide.
  • the terms induced and stimulated are used interchangeably throughout the specification.
  • the BH3 domain peptide is attached to a transduction domain.
  • a transduction domain directs a peptide in which it is present to a desired cellular destination.
  • the transduction domain can direct the peptide across the plasma membrane, e.g., from outside the cell, through the plasma membrane, and into the cytoplasm.
  • the transduction domain can direct the peptide to a desired location within the cell, e.g., the nucleus, the ribosome, the ER, mitochondria, a lysosome, or peroxisome.
  • the transduction domain is derived from a known membrane-translocating sequence.
  • transduction domain is a compound that is known to facilitate membrane uptake such as polyethylene glycol, cholesterol moieties, octanoic acid and decanoic acid.
  • the transduction domain may be linked either to the N-terminal or the C-terminal end of BH3 domain peptide.
  • the BH3 domain peptides and/or the transduction domain peptides can be polymers of L-amino acids, D-amino acids, or a combination of both.
  • the BH3 domain peptides and/or the transduction domain peptides are cyclic peptides.
  • Cyclic peptides are prepared by methods known in the art. For example, macrocyclization is often accomplished by forming an amide bond between the peptide N- and C-termini, between a side chain and the N- or C-terminus [e.g., with K3Fe(CN)6 at pH 8.5] ( Samson et al., Endocrinology, 137: 5182-5185 (1996 )), or between two amino acid side chains. See, e.g., DeGrado, Adv Protein Chem, 39: 51-124 (1988 ).
  • BH3 domain peptides and/or the transduction domain peptides are prepared using modern cloning techniques, or may be synthesized by solid state methods or by site-directed mutagenesis.
  • native BH3 domain peptides and/or transduction domain peptides can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques.
  • BH3 domain polypeptides and/or transduction domain peptides are produced by recombinant DNA techniques.
  • BH3 domain peptides and/or transduction domain peptides can be synthesized chemically using standard peptide synthesis techniques.
  • the BH3 peptide maintains its secondary structure, e.g., ⁇ -helical structure.
  • Methods of helix stabilization are known in the art.
  • An “isolated” or “purified” BH3 domain peptide is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the BH3 domain peptide is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized.
  • kits for performing BH3 Profiling may comprise a multi-well plate having an agent and a BH3 domain peptide.
  • the kit may comprise a multi-well plate having an agent.
  • the agent may be a chemotherapeutic agent.
  • the kit may comprise a multi-well plate having at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10 agents.
  • the kit may comprise a multi-well plate, wherein each well of the plate comprises a different agent.
  • the kit may comprise a multi-well plate having a BH3 domain peptide.
  • the BH3 domain peptide may be derived from the BH3 domain of a BID, a BIM, a BAD, a NOXA, a PUMA a BMF, or a HRK polypeptide.
  • the BH3 domain peptide may be selected from the group consisting of SEQ ID NO: 1-15.
  • the kit may further comprise a vial containing a BH3 profiling buffer.
  • the vial is a glass or plastic vial.
  • the vial may comprise volumetric markings on its surface.
  • the BH3 profiling buffer may be supplemented with a permeabilizing agent.
  • the permeabilizing agent may be digitonin or saponin.
  • the kit may further comprise a potentiometric dye.
  • the potentiometric dye may be 5,5',6,6'- tetrachloro-l,l',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1), dihydrorhodamine 123, tetramethylrhodamine methyl ester (TMRM) or tetramethylrhodamine ethyl ester (TMRE).
  • the kit may further comprise an antibody for cytochrome c, SMAC/Diablo, Omi, adenylate kinase-2 or apoptosis-inducing factor.
  • kit may further comprise instructions for using the kit to predict the sensitivity of cells to an agent.
  • Instructions are generally provided as a printed pamphlet or paper sheet but may also include any oral or electronic instructions provided in any manner such that a user will clearly recognize that the instructions are to be associated with the kit, for example, audiovisual (e.g., videotape, DVD, etc.), Internet, and/or web-based communications, etc.
  • Example 1 Predicting toxicity in normal cells with dynamic BH3 profiling
  • FIGs. 1A-D cytochrome c immunofluorescence
  • FIG. 1E An exemplary dose-response curve of cytochrome c loss for increasing concentrations of the synthetic Bim BH3 peptide is depicted in FIG. 1E (standard deviations depicted as error bars). Note that at low concentrations of the Bim peptide there is little or no loss of cytochrome c, whereas at high peptide concentrations a complete loss of cytochrome c is observed.
  • FIG. 2A depicts an exemplary histogram of the increases in cell death sensitivity (delta priming) represented by values of delta percent priming, with FIG 2B representing a zoomed view of the y-axis of the histogram (percentage of compounds in the library).
  • the drug treated healthy HFF cells show an increase in cell death sensitivity compared to the healthy cells treated with DMSO (the inactive chemical) with approximately 2.41% of compounds tested. This indicates that molecules that increase cell death sensitivity in healthy cells relative to a control compound that has no effect can be reliably detected.
  • FIG. 2 A comparison of drug induced changes in BH3 profiles between mouse mammary tumor cells (y-axis) and healthy human foreskin fibroblasts (x-axis) is depicted in FIG. 3 .
  • y-axis mouse mammary tumor cells
  • x-axis healthy human foreskin fibroblasts
  • BH3 profiling on healthy adult mouse hepatocytes was examined by measuring the loss of cytochrome c from mitochondria in response to the synthetic BH3 peptides. To do this, immunofluorescence for cytochrome c was assessed at increasing concentrations of Bim BH3 peptide (0.1 ⁇ M ( FIG. 4A ), 1.56 ⁇ M ( FIG. 4B ), 25 ⁇ M ( FIG. 4C ), and 100 ⁇ M ( FIG. 4D )). A dose-response curve of cytochrome c loss is depicted in FIG. 4E . Note that at low concentrations of the Bim peptide, there is little or no loss of cytochrome c, whereas at high peptide concentrations a complete loss of cytochrome c is observed.
  • FIGs. 5A-D Freshly isolated adult mouse hepatocytes were treated with different drugs for 20 hours, and the loss of cytochrome c induced by a single concentration of the synthetic Bim BH3 peptide was subsequently assessed by immunofluorescence ( FIGs. 5A-D ). Increase in cell death sensitivity is indicated by loss of cytochrome c, which is quantified as an increase in apoptotic sensitivity (delta priming, FIG. 5E ). Navitoclax, doxorubicin, and tanespimycin all increase apoptotic sensitivity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Claims (15)

  1. Méthode de criblage d'une pluralité d'agents permettant de déterminer la toxicité, ladite méthode comprenant :
    a) la fourniture d'une pluralité d'agents ;
    b) la fourniture d'une aliquote d'essai d'un échantillon de cellules pour chacun de la pluralité d'agents, ledit échantillon de cellules étant constitué de cellules non cancéreuses préalablement prélevées chez un sujet ;
    c) la mise en contact séparément de chaque aliquote d'essai avec son agent respectif ;
    d) la fourniture d'une aliquote témoin de l'échantillon de cellules, ladite aliquote témoin n'étant pas mise en contact avec l'un quelconque de la pluralité d'agents ;
    e) la perméabilisation des cellules dans chaque aliquote ;
    f) la mise en contact des cellules perméabilisées avec un peptide pro-apoptotique du domaine d'homologie 3 de Bcl-2 (BH3) ;
    g) la détermination d'une valeur du pourcentage de la perméabilisation de la membrane externe mitochondriale (MOMP) induite par le peptide du domaine BH3 dans les cellules dans chacune des aliquotes d'essai ;
    h) la détermination d'une valeur du pourcentage de la MOMP induite par le peptide du domaine BH3 dans les cellules dans l'aliquote témoin ; et
    i) la détermination d'une valeur du pourcentage d'amorçage delta pour chacune des aliquotes d'essai, ledit pourcentage d'amorçage delta étant la différence entre la valeur du pourcentage de la MOMP déterminée en (g) et la valeur du pourcentage de la MOMP déterminée en (h),
    un pourcentage d'amorçage delta supérieur à 20 pour cent indiquant que l'agent avec lequel les cellules dans l'aliquote d'essai ont été mises en contact est toxique pour les cellules.
  2. Méthode selon la revendication 1, comprenant en outre la réalisation d'essais de toxicité in vivo avec l'agent chez un animal non humain ou d'essais de toxicité in vitro avec l'agent si le pourcentage d'amorçage delta est inférieur ou égal à 20 pour cent, inférieur ou égal à 18 pour cent, inférieur ou égal à 16 pour cent, inférieur ou égal à 14 pour cent, inférieur ou égal à 12 pour cent, inférieur ou égal à 10 pour cent, inférieur ou égal à 8 pour cent, inférieur ou égal à 6 pour cent, inférieur ou égal à 4 pour cent, inférieur ou égal à 2 pour cent, ou inférieur ou égal à 1 pour cent ; et/ou lesdites cellules non cancéreuses étant des cellules saines.
  3. Méthode selon l'une quelconque des revendications 1 à 2, comprenant en outre :
    j) la fourniture d'une aliquote d'essai d'un échantillon de cellules cancéreuses préalablement prélevé chez un sujet pour chacun de la pluralité d'agents ;
    k) la mise en contact séparément de chaque aliquote d'essai avec son agent respectif ;
    1) la fourniture d'une aliquote témoin de l'échantillon de cellules cancéreuses, ladite aliquote témoin n'étant pas mise en contact avec l'un quelconque de la pluralité d'agents ;
    m) la perméabilisation des cellules cancéreuses dans chaque aliquote ;
    n) la mise en contact des cellules cancéreuses perméabilisées avec un peptide du domaine BH3 pro-apoptotique ;
    o) la détermination d'une valeur du pourcentage de la MOMP induite par le peptide du domaine BH3 dans les cellules cancéreuses dans chacune des aliquotes d'essai ;
    p) la détermination d'une valeur du pourcentage de la MOMP induite par le peptide du domaine BH3 dans les cellules cancéreuses dans l'aliquote témoin ; et
    q) la détermination d'une valeur du pourcentage d'amorçage delta pour chacune des aliquotes d'essai, ledit pourcentage d'amorçage delta étant la différence entre la valeur du pourcentage de la MOMP déterminée en (o) et la valeur du pourcentage de la MOMP déterminée en (p),
    un pourcentage d'amorçage delta supérieur à 20 pour cent indiquant que l'agent avec lequel les cellules cancéreuses dans l'aliquote d'essai ont été mises en contact est toxique pour les cellules cancéreuses.
  4. Méthode selon la revendication 3, comprenant en outre la réalisation d'essais de toxicité in vivo avec l'agent chez un animal non humain ou dans des essais de toxicité in vitro avec l'agent si :
    i) le pourcentage d'amorçage delta dans les cellules cancéreuses est supérieur à 20 pour cent, supérieur à 30 pour cent, supérieur à 40 pour cent, supérieur à 50 pour cent, supérieur à 60 pour cent, supérieur à 70 pour cent, supérieur à 80 pour cent, supérieur à 90 pour cent, supérieur à 95 pour cent, ou 100 pour cent ; ou
    ii) le pourcentage d'amorçage delta dans les cellules cancéreuses est supérieur au pourcentage d'amorçage delta dans les cellules non cancéreuses ; ou
    iii) le pourcentage d'amorçage delta dans les cellules cancéreuses est supérieur ou égal à 10 %, supérieur ou égal à 20 %, supérieur ou égal à 30 %, supérieur ou égal à 40 %, supérieur ou égal à 50 %, supérieur ou égal à 60 %, supérieur ou égal à 70 %, supérieur ou égal à 80 %, supérieur ou égal à 90 %, supérieur ou égal à 100 %, supérieur ou égal à 150 %, ou supérieur ou égal à 200 %, supérieur au pourcentage d'amorçage delta dans les cellules non cancéreuses ; ou
    iv) le pourcentage d'amorçage delta dans les cellules cancéreuses est supérieur ou égal à 2 fois, supérieur ou égal à 3 fois, supérieur ou égal à 4 fois, supérieur ou égal à 5 fois, supérieur ou égal à 6 fois, supérieur ou égal à 7 fois, supérieur ou égal à 8 fois, supérieur ou égal à 9 fois ou supérieur ou égal à 10 fois le pourcentage d'amorçage delta dans les cellules non cancéreuses.
  5. Méthode selon l'une quelconque des revendications 3 à 4, lesdites cellules cancéreuses étant des cellules tumorales humaines primaires ; ou lesdites cellules cancéreuses étant prélevées sur une xénogreffe dérivée d'un patient (PDX).
  6. Méthode selon l'une quelconque des revendications 1 à 5 :
    i) ladite pluralité d'agents comprenant 20 agents ou plus ; et/ou
    ii) ladite pluralité d'agents comprenant 100 agents ou plus ; et/ou
    iii) chaque aliquote d'essai étant mise en contact avec son agent respectif pendant 24 heures ou moins ; et/ou
    iv) lesdites cellules perméabilisées étant mises en contact avec le peptide du domaine BH3 pro-apoptotique pendant 3 heures ou moins ; et/ou
    v) lesdites cellules de chacune des aliquotes d'essai étant perméabilisées avec de la digitonine ou de la saponine.
  7. Méthode selon l'une quelconque des revendications 1 à 6, ledit pourcentage de la MOMP induite par le peptide du domaine BH3 étant déterminé par une ou plusieurs parmi :
    i) la mise en contact des cellules avec un colorant potentiométrique et la mesure de l'émission dudit colorant potentiométrique, ledit colorant potentiométrique étant choisi dans le groupe constitué par l'iodure de 5,5',6,6'-tétrachloro-1,1',3,3'-tétraéthylbenzimidazolylcarbocyanine (JC-1), la dihydrorhodamine 123, l'ester méthylique de tétraméthylrhodamine (TMRM) ou l'ester éthylique de tétraméthylrhodamine (TMRE) ;
    ii) la mesure de la libération d'une molécule provenant de l'espace intermembranaire mitochondrial, ladite molécule provenant de l'espace intermembranaire mitochondrial étant choisie dans le groupe constitué par le cytochrome c, le SMAC/Diablo, l'Omi, l'adénylate kinase-2 ou le facteur inducteur de l'apoptose ; et
    iii) la mesure de la rétention d'une molécule provenant de l'espace intermembranaire mitochondrial, ladite molécule provenant de l'espace intermembranaire mitochondrial étant choisie dans le groupe constitué par le cytochrome c, le deuxième activateur de caspases dérivé de mitochondries (SMAC)/Diablo, l'Omi, l'adénylate kinase-2, ou le facteur inducteur de l'apoptose.
  8. Méthode selon l'une quelconque des revendications 1 à 7 :
    i) ledit peptide du domaine BH3 étant dérivé du domaine BH3 d'un agoniste de mort à domaine d'interaction BH3 (BID), d'un médiateur de mort cellulaire interagissant avec Bcl-2 (BIM), d'un promoteur de mort associé à Bcl-2 (BAD), d'une Noxa, d'un modulateur de l'apoptose régulé positivement par p53 (PUMA), d'un facteur modificateur de Bcl-2 (BMF) ou d'un polypeptide harakiri (HRK) ; et/ou
    ii) ledit peptide du domaine BH3 étant choisi dans le groupe constitué par les SEQ ID n° : 1 à 16 ; et/ou
    iii) un agent parmi ladite pluralité d'agents comprenant un ou plusieurs composés ; et/ou
    iv) un agent parmi ladite pluralité d'agents étant un agent anticancéreux ; et/ou
    v) un agent parmi ladite pluralité d'agents étant un agent chimiothérapeutique ; et/ou
    vi) un ou plusieurs agents parmi ladite pluralité d'agents étant choisis parmi les petites molécules organiques, les petites molécules inorganiques, les peptides, les protéines, les analogues de protéines, les enzymes, les acides nucléiques, les analogues d'acide nucléique, les anticorps, les antigènes, les hormones, les lipides, les polysaccharides, les facteurs de croissance, les virus, les cellules, les agents bioactifs, les agents pharmaceutiques, et les combinaisons et promédicaments de ceux-ci ; et/ou
    vii) un ou plusieurs agents parmi ladite pluralité d'agents étant choisis parmi les gaz, les particules fines, un rayonnement, un rayonnement électromagnétique et les aérosols.
  9. Méthode de prédiction de la toxicité d'un agent pour un tissu, ladite méthode comprenant :
    a) la fourniture d'un agent ;
    b) la fourniture d'une aliquote d'essai de chacun d'une pluralité d'échantillons de cellules, chaque échantillon de cellules comprenant des cellules non cancéreuses préalablement prélevées sur un tissu d'un sujet ;
    c) la mise en contact séparément de chaque aliquote d'essai avec l'agent ;
    d) la fourniture d'une aliquote témoin de chacun de la pluralité d'échantillons de cellules, ladite aliquote témoin n'étant pas mise en contact avec l'agent ;
    e) la perméabilisation des cellules dans chaque aliquote d'essai et aliquote témoin ;
    f) la mise en contact des cellules perméabilisées avec un peptide du domaine BH3 pro-apoptotique ;
    g) la détermination d'une valeur du pourcentage de la MOMP induite par le peptide du domaine BH3 dans les cellules dans chaque aliquote d'essai ;
    h) la détermination d'une valeur du pourcentage de la MOMP induite par le peptide du domaine BH3 dans les cellules dans chaque aliquote témoin ; et
    i) la détermination d'une valeur du pourcentage d'amorçage delta pour chaque aliquote d'essai, ledit pourcentage d'amorçage delta étant la différence entre la valeur du pourcentage de la MOMP déterminée en (g) et la valeur du pourcentage de la MOMP déterminée en (h),
    un pourcentage d'amorçage delta supérieur à 20 pour cent indiquant que l'agent est toxique pour le tissu sur lequel les cellules ont été prélevées.
  10. Méthode selon la revendication 9, comprenant en outre la réalisation d'essais de toxicité in vivo avec l'agent chez un animal non humain ou d'essais de toxicité in vitro avec l'agent si le pourcentage d'amorçage delta est inférieur ou égal à 20 pour cent, inférieur ou égal à 18 pour cent, inférieur ou égal à 16 pour cent, inférieur ou égal à 14 pour cent, inférieur ou égal à 12 pour cent, inférieur ou égal à 10 pour cent, inférieur ou égal à 8 pour cent, inférieur ou égal à 6 pour cent, inférieur ou égal à 4 pour cent, inférieur ou égal à 2 pour cent, ou inférieur ou égal à 1 pour cent.
  11. Méthode selon la revendication 9 ou 10 :
    i) lesdites cellules non cancéreuses étant des cellules saines ; et/ou
    ii) lesdites cellules étant des cellules de mammifères ; et/ou
    iii) lesdites cellules étant dérivées d'échantillons prélevés par biopsie ou autopsie d'un animal ; et/ou
    iv) lesdites cellules de chaque aliquote d'essai étant mises en contact avec l'agent pendant 24 heures ou moins ; et/ou
    v) lesdites cellules perméabilisées étant mises en contact avec le peptide du domaine BH3 pro-apoptotique pendant 3 heures ou moins ; et/ou
    vi) lesdites cellules étant perméabilisées avec de la digitonine ou de la saponine.
  12. Méthode selon l'une quelconque des revendications 9 à 11, ledit pourcentage de la MOMP induite par le peptide du domaine BH3 étant déterminé par une ou plusieurs parmi :
    i) la mise en contact des cellules avec un colorant potentiométrique et la mesure de l'émission dudit colorant potentiométrique, ledit colorant potentiométrique étant choisi dans le groupe constitué par l'iodure de 5,5',6,6'-tétrachloro-1,1',3,3'-tétraéthylbenzimidazolylcarbocyanine (JC-1), la dihydrorhodamine 123, l'ester méthylique de tétraméthylrhodamine (TMRM) ou l'ester éthylique de tétraméthylrhodamine (TMRE) ;
    ii) la mesure de la libération d'une molécule provenant de l'espace intermembranaire mitochondrial, ladite molécule provenant de l'espace intermembranaire mitochondrial étant choisie dans le groupe constitué par le cytochrome c, le SMAC/Diablo, l'Omi, l'adénylate kinase-2 ou le facteur inducteur de l'apoptose ; et
    iii) la mesure de la rétention d'une molécule provenant de l'espace intermembranaire mitochondrial, ladite molécule provenant de l'espace intermembranaire mitochondrial étant choisie dans le groupe constitué par le cytochrome c, le SMAC/Diablo, l'Omi, l'adénylate kinase-2 ou le facteur inducteur de l'apoptose.
  13. Méthode selon l'une quelconque des revendications 9 à 12 :
    i) ledit peptide du domaine BH3 étant dérivé du domaine BH3 d'un BID, d'un BIM, d'un BAD, d'une NOXA, d'un PUMA, d'un BMF ou d'un polypeptide HRK ; et/ou
    ii) ledit peptide du domaine BH3 étant choisi dans le groupe constitué par les SEQ ID n° : 1 à 16 ; et/ou
    iii) ledit agent comprenant un ou plusieurs composés ; et/ou
    iv) ledit agent étant un agent anticancéreux ; et/ou
    v) ledit agent étant un agent chimiothérapeutique ; et/ou
    vi) ledit agent étant une petite molécule organique, une petite molécule inorganique, un peptide, une protéine, un analogue de protéine, une enzyme, un acide nucléique, un analogue d'acide nucléique, un anticorps, un antigène, une hormone, un lipide, un polysaccharide, un facteur de croissance, un virus, une cellule, un agent bioactif, un agent pharmaceutique, ou une combinaison ou un promédicament de ceux-ci ; et/ou
    vii) ledit agent étant un gaz, des particules fines, un rayonnement, un rayonnement électromagnétique ou un aérosol.
  14. Méthode de prédiction de la toxicité d'un agent, ladite méthode comprenant :
    a) la fourniture d'un ou plusieurs échantillons de cellules, chaque échantillon de cellules comprenant des cellules non cancéreuses préalablement prélevées sur un tissu provenant d'un animal non humain qui a été mis en contact avec une dose sublétale d'un agent puis a été sacrifié ;
    b) la fourniture d'une aliquote d'essai de chacun desdits un ou plusieurs échantillons de cellules ;
    c) la mise en contact séparément de chaque aliquote d'essai avec l'agent ;
    d) la fourniture d'une aliquote témoin de chacun desdits un ou plusieurs échantillons de cellules, ladite aliquote témoin n'étant pas mise en contact avec l'agent ;
    e) la perméabilisation des cellules dans chaque aliquote ;
    f) la mise en contact des cellules perméabilisées avec un peptide du domaine BH3 pro-apoptotique ;
    g) la déterminer d'une valeur du pourcentage de la MOMP induite par le peptide du domaine BH3 dans les cellules dans l'aliquote d'essai ;
    h) la détermination d'une valeur du pourcentage de la MOMP induite par le peptide du domaine BH3 dans les cellules dans l'aliquote témoin ; et
    i) la détermination d'une valeur du pourcentage d'amorçage delta pour l'aliquote d'essai, ledit pourcentage d'amorçage delta étant la différence entre la valeur du pourcentage de la MOMP déterminée en (g) et la valeur du pourcentage de la MOMP déterminée en (h),
    un pourcentage d'amorçage delta supérieur à 20 pour cent indiquant que l'agent est toxique pour le tissu de l'animal non humain sur lequel les cellules ont été prélevées.
  15. Méthode selon la revendication 14 :
    i) ledit animal non humain qui a été mis en contact avec une dose sublétale d'un agent étant un mammifère, ledit mammifère étant éventuellement un primate non humain ou un rongeur ; et/ou
    ii) ledit animal non humain ayant été mis en contact avec l'agent par injection, inhalation, administration topique ou administration orale ; et/ou
    iii) ledit animal non humain étant en contact avec l'agent pendant 24 heures ou moins ; et/ou
    iv) lesdites cellules perméabilisées étant mises en contact avec le peptide du domaine BH3 pro-apoptotique pendant 3 heures ou moins ; et/ou
    v) lesdites cellules étant perméabilisées à la digitonine ou à la saponine ; et/ou
    vi) ledit peptide du domaine BH3 étant dérivé du domaine BH3 d'un BID, d'un BIM, d'un BAD, d'une NOXA, d'un PUMA, d'un BMF ou d'un polypeptide HRK ; et/ou
    vii) ledit peptide du domaine BH3 étant choisi dans le groupe constitué par les SEQ ID n° : 1 à 16 ; et/ou
    viii) ledit agent comprenant un ou plusieurs composés ; et/ou
    ix) ledit agent étant un agent anticancéreux ; et/ou
    x) ledit agent étant un agent chimiothérapeutique ; et/ou
    xi) ledit agent étant une petite molécule organique, une petite molécule inorganique, un peptide, une protéine, un analogue de protéine, une enzyme, un acide nucléique, un analogue d'acide nucléique, un anticorps, un antigène, une hormone, un lipide, un polysaccharide, un facteur de croissance, un virus, une cellule, un agent bioactif, un agent pharmaceutique, ou une combinaison ou un promédicament de ceux-ci ; et/ou
    xii) ledit agent étant un gaz, des particules fines, un rayonnement, un rayonnement électromagnétique ou un aérosol.
EP16787045.0A 2015-04-27 2016-04-27 Compositions et méthodes d'évaluation de toxicité au moyen d'un profilage bh3 dynamique Active EP3289094B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562153475P 2015-04-27 2015-04-27
PCT/US2016/029510 WO2016176299A1 (fr) 2015-04-27 2016-04-27 Compositions et méthodes d'évaluation de toxicité au moyen d'un profilage bh3 dynamique

Publications (3)

Publication Number Publication Date
EP3289094A1 EP3289094A1 (fr) 2018-03-07
EP3289094A4 EP3289094A4 (fr) 2018-10-31
EP3289094B1 true EP3289094B1 (fr) 2024-06-05

Family

ID=57198812

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16787045.0A Active EP3289094B1 (fr) 2015-04-27 2016-04-27 Compositions et méthodes d'évaluation de toxicité au moyen d'un profilage bh3 dynamique
EP16787039.3A Active EP3288964B1 (fr) 2015-04-27 2016-04-27 Profilage bh3 à haut rendement : une technologie rapide et échelonnable pour un profil bh3 sur un faible nombre de cellules

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP16787039.3A Active EP3288964B1 (fr) 2015-04-27 2016-04-27 Profilage bh3 à haut rendement : une technologie rapide et échelonnable pour un profil bh3 sur un faible nombre de cellules

Country Status (6)

Country Link
US (4) US20180120297A1 (fr)
EP (2) EP3289094B1 (fr)
JP (3) JP6802185B2 (fr)
AU (2) AU2016253957C1 (fr)
CA (1) CA2983022C (fr)
WO (2) WO2016176299A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171809A1 (en) 2002-09-09 2004-09-02 Korsmeyer Stanley J. BH3 peptides and method of use thereof
JP2009532033A (ja) 2006-03-31 2009-09-10 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 細胞の化学感受性を定量する方法
HK1213046A1 (zh) 2012-09-19 2016-06-24 Dana-Farber Cancer Institute, Inc. 動態bh3分析
US10739333B2 (en) 2013-09-19 2020-08-11 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
CN107406881B (zh) 2015-01-12 2021-05-25 尤特罗皮克斯制药股份有限公司 用于指导癌症治疗的内容相关的诊断测试
CA2979999A1 (fr) 2015-03-18 2016-09-22 Massachusetts Institute Of Technology Peptides de liaison a mcl-1 selectifs
WO2016172214A1 (fr) 2015-04-20 2016-10-27 Tolero Pharmaceuticals, Inc. Prédiction de la réaction à l'alvocidib par identification de profil mitochondrial
US20180120297A1 (en) 2015-04-27 2018-05-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using dynamic bh3 profiling
RU2752729C2 (ru) 2015-05-18 2021-07-30 Сумитомо Даиниппон Фарма Онколоджи, Инк. Пролекарства альвоцидиба, имеющие повышенную биодоступность
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US10132797B2 (en) * 2016-12-19 2018-11-20 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
WO2020060975A1 (fr) * 2018-09-17 2020-03-26 Massachusetts Institute Of Technology Peptides sélectifs pour des protéines de la famille bcl-2
CN113490499A (zh) 2018-12-04 2021-10-08 大日本住友制药肿瘤公司 用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
WO2020176689A1 (fr) * 2019-02-26 2020-09-03 Dana-Farber Cancer Institute, Inc. Profilage de bh3 dynamique par imagerie de cellules vivantes
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
US6184038B1 (en) 1995-07-28 2001-02-06 Marie Curie Cancer Care Transport proteins and their uses
WO1997015831A1 (fr) 1995-10-24 1997-05-01 Sangstat Medical Corporation Technique de filtrage anti alpha-galactosyle
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
JP2001524301A (ja) 1997-09-17 2001-12-04 ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ 新規治療用分子
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1210098A1 (fr) 1999-04-07 2002-06-05 Thomas Jefferson University Amelioration de la fixation cellulaire
AU6906100A (en) 1999-08-16 2001-03-13 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis
WO2002020568A2 (fr) 2000-09-06 2002-03-14 Abbott Laboratories Peptides mutants derives de bad et leur utilisation pour identifier des substances se liant a un element de la famille de proteines bcl-2
AU2002258399A1 (en) 2001-02-16 2002-09-19 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
AU2002361589A1 (en) 2001-11-06 2003-05-19 Enanta Pharmaceuticals, Inc. Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
WO2003055515A1 (fr) 2001-12-21 2003-07-10 Arius Research, Inc. Anticorps anticancereux personnalises
US20040171809A1 (en) 2002-09-09 2004-09-02 Korsmeyer Stanley J. BH3 peptides and method of use thereof
US20070032417A1 (en) 2002-12-24 2007-02-08 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
EP1608969A4 (fr) * 2003-03-19 2007-06-06 Alfa Wassermann Inc Separation et accumulation de composants sub-cellulaires, et proteines qui en sont tirees
DK2332968T3 (en) 2003-11-05 2016-08-22 Dana Farber Cancer Inst Inc Alpha-helix peptides suitable for activating or inhibiting cell death
US7714005B2 (en) 2004-12-22 2010-05-11 The Ohio State University Research Foundation Small molecule Bcl-xL/Bcl-2 binding inhibitors
JP2005130867A (ja) * 2005-02-16 2005-05-26 Mitokor ミトコンドリア内カルシウムを使用するスクリーニングアッセイ
WO2006099667A1 (fr) 2005-03-21 2006-09-28 The Walter And Eliza Hall Institute Of Medical Research Agents prophylactiques et therapeutiques et leurs utilisations
US20070027175A1 (en) 2005-07-27 2007-02-01 Shaughnessy John Jr Antineoplastic activities of ellipticine and its derivatives
JP2009532033A (ja) * 2006-03-31 2009-09-10 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 細胞の化学感受性を定量する方法
US8518635B2 (en) 2006-06-12 2013-08-27 The J. David Gladstone Institutes Regulation of protein activity by reversible acetylation
KR100786759B1 (ko) * 2006-07-07 2007-12-18 김현기 Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물
US9360473B2 (en) 2006-08-16 2016-06-07 Eutropics Pharmaceuticals, Inc. Assay system to identify therapeutic agents
WO2008152405A2 (fr) 2007-06-15 2008-12-18 The Queen's University Of Belfast Cible anti-cancer
EP2200653A2 (fr) 2007-09-10 2010-06-30 University of Massachusetts Agents antitumoraux ciblant les mitochondries
US8921323B2 (en) 2007-09-26 2014-12-30 Dana Farber Cancer Institute, Inc. Methods and compositions for modulating BCL-2 family polypeptides
JP2009240173A (ja) * 2008-03-28 2009-10-22 Univ Of Tokushima パーキン蛋白の新規糖化因子
KR20210019599A (ko) * 2009-06-11 2021-02-22 미네르바 바이오테크놀로지 코포레이션 줄기세포 및 전구세포를 배양하는 방법
WO2010147961A1 (fr) 2009-06-15 2010-12-23 Precision Therapeutics, Inc. Procédés et marqueurs pour prédire des réponses à une chimiothérapie
US20130122492A1 (en) * 2011-11-14 2013-05-16 Kellbenx Inc. Detection, isolation and analysis of rare cells in biological fluids
EP2847592A4 (fr) * 2012-05-10 2016-05-04 Eutropics Pharmaceuticals Inc Essai de diagnostic fonctionnel de substitut pour le cancer
US20150322479A1 (en) * 2012-06-20 2015-11-12 Cytospan Technologies Corporation Apparatus and method for quantification of replicative lifespan and observation of senescene
HK1213046A1 (zh) 2012-09-19 2016-06-24 Dana-Farber Cancer Institute, Inc. 動態bh3分析
JP6327662B2 (ja) * 2012-09-26 2018-05-23 学校法人藤田学園 細胞表面タンパクを抗原とする抗体を測定する方法
JP2016526892A (ja) * 2013-07-18 2016-09-08 ユートロピクス ファーマシューティカルズ， インコーポレイテッド 示差的ｂｈ３ミトコンドリアプロファイリング
US10739333B2 (en) 2013-09-19 2020-08-11 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
US20180120297A1 (en) 2015-04-27 2018-05-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using dynamic bh3 profiling
US11092602B2 (en) 2015-07-06 2021-08-17 Whitehead Institute For Biomedical Research Methods and compositions relating to proteasome inhibitor resistance
WO2020176689A1 (fr) 2019-02-26 2020-09-03 Dana-Farber Cancer Institute, Inc. Profilage de bh3 dynamique par imagerie de cellules vivantes

Also Published As

Publication number Publication date
EP3288964A4 (fr) 2018-10-31
JP6802185B2 (ja) 2020-12-16
JP2021036915A (ja) 2021-03-11
HK1252058A1 (en) 2019-05-10
US20210255167A1 (en) 2021-08-19
US20180120297A1 (en) 2018-05-03
EP3289094A4 (fr) 2018-10-31
AU2016253957A1 (en) 2017-10-19
CA2983022A1 (fr) 2016-11-03
EP3288964A1 (fr) 2018-03-07
EP3289094A1 (fr) 2018-03-07
JP6814745B2 (ja) 2021-01-20
US20210041419A1 (en) 2021-02-11
JP2018514210A (ja) 2018-06-07
WO2016176299A1 (fr) 2016-11-03
US10761086B2 (en) 2020-09-01
HK1252055A1 (en) 2019-05-10
US20180128813A1 (en) 2018-05-10
AU2016253957B2 (en) 2020-10-22
AU2016255749B2 (en) 2021-10-14
JP2018520638A (ja) 2018-08-02
WO2016176288A1 (fr) 2016-11-03
EP3288964B1 (fr) 2024-02-21
AU2016253957C1 (en) 2021-04-01
AU2016255749A1 (en) 2017-10-19
US11867688B2 (en) 2024-01-09
CA2983022C (fr) 2023-03-07
CA2983024A1 (fr) 2016-11-03

Similar Documents

Publication Publication Date Title
US20210255167A1 (en) Compositions and methods for assessing toxicity using dynamic bh3 profiling
US20180318386A1 (en) Peptides and methods of treating endometriosis using the same
JP7589159B2 (ja) ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング
US7176035B2 (en) Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction
CA2983024C (fr) Compositions et methodes d'evaluation de toxicite au moyen d'un profilage bh3 dynamique
HK1252055B (en) Compositions and methods for assessing toxicity using dynamic bh3 profiling
US20040265917A1 (en) Methods of measuring the ability of a test compound to inactivate a biological target in cells of a subject
HK1252058B (en) High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells
KR101444995B1 (ko) 세포질 단백질의 단백질-단백질 상호작용을 확인하는 방법
CN114761809B (zh) 预测bcl2家族蛋白靶向药物的反应性的方法
Ceylan et al. Human jejunal enteroids for studies of epithelial drug transport and metabolism
US11447550B2 (en) Peptides for molecular detection of PD-L1
US20170336406A1 (en) Pif binding as a marker for immune dysregulation
KR101432714B1 (ko) 벤조안트라센 오염 검출을 위한 마커 및 키트
JP6175144B2 (ja) 分子のプールの選択方法
JP2012115195A (ja) バセドウ病の検査方法、バセドウ病の予防薬または治療薬のスクリーニング方法、およびバセドウ病検査用のキット

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170929

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181004

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101AFI20180927BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1252055

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200219

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230906

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20231005

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240126

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RYAN, JEREMY

Inventor name: BHOLA, PATRICK

Inventor name: LETAI, ANTHONY

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016087861

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240905

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240906

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1692814

Country of ref document: AT

Kind code of ref document: T

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241005

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241005

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016087861

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

26N No opposition filed

Effective date: 20250306

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250429

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250428

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250425

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250501

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250427